Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

All-trans retinoic acid - ATRA- is known to remodulate the stroma of pancreatic cancer in mice. Here, the authors carried out a Phase Ib trial in pancreatic patients and show that ATRA in combination with chemotherapy is a safe potential treatment for patients with advanced pancreatic cancer, and de...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hemant M. Kocher, Bristi Basu, Fieke E. M. Froeling, Debashis Sarker, Sarah Slater, Dominic Carlin, Nandita M. deSouza, Katja N. De Paepe, Michelle R. Goulart, Christine Hughes, Ahmet Imrali, Rhiannon Roberts, Maria Pawula, Richard Houghton, Cheryl Lawrence, Yathushan Yogeswaran, Kelly Mousa, Carike Coetzee, Peter Sasieni, Aaron Prendergast, David J. Propper
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/7c7d3ad82a9e4375ae3a8da492b9ac27
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7c7d3ad82a9e4375ae3a8da492b9ac27
record_format	dspace
spelling	oai:doaj.org-article:7c7d3ad82a9e4375ae3a8da492b9ac272021-12-02T18:48:25ZPhase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer10.1038/s41467-020-18636-w2041-1723https://doaj.org/article/7c7d3ad82a9e4375ae3a8da492b9ac272020-09-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-18636-whttps://doaj.org/toc/2041-1723All-trans retinoic acid - ATRA- is known to remodulate the stroma of pancreatic cancer in mice. Here, the authors carried out a Phase Ib trial in pancreatic patients and show that ATRA in combination with chemotherapy is a safe potential treatment for patients with advanced pancreatic cancer, and demonstrate a stromal modulatory effect.Hemant M. KocherBristi BasuFieke E. M. FroelingDebashis SarkerSarah SlaterDominic CarlinNandita M. deSouzaKatja N. De PaepeMichelle R. GoulartChristine HughesAhmet ImraliRhiannon RobertsMaria PawulaRichard HoughtonCheryl LawrenceYathushan YogeswaranKelly MousaCarike CoetzeePeter SasieniAaron PrendergastDavid J. PropperNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Hemant M. Kocher Bristi Basu Fieke E. M. Froeling Debashis Sarker Sarah Slater Dominic Carlin Nandita M. deSouza Katja N. De Paepe Michelle R. Goulart Christine Hughes Ahmet Imrali Rhiannon Roberts Maria Pawula Richard Houghton Cheryl Lawrence Yathushan Yogeswaran Kelly Mousa Carike Coetzee Peter Sasieni Aaron Prendergast David J. Propper Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
description	All-trans retinoic acid - ATRA- is known to remodulate the stroma of pancreatic cancer in mice. Here, the authors carried out a Phase Ib trial in pancreatic patients and show that ATRA in combination with chemotherapy is a safe potential treatment for patients with advanced pancreatic cancer, and demonstrate a stromal modulatory effect.
format	article
author	Hemant M. Kocher Bristi Basu Fieke E. M. Froeling Debashis Sarker Sarah Slater Dominic Carlin Nandita M. deSouza Katja N. De Paepe Michelle R. Goulart Christine Hughes Ahmet Imrali Rhiannon Roberts Maria Pawula Richard Houghton Cheryl Lawrence Yathushan Yogeswaran Kelly Mousa Carike Coetzee Peter Sasieni Aaron Prendergast David J. Propper
author_facet	Hemant M. Kocher Bristi Basu Fieke E. M. Froeling Debashis Sarker Sarah Slater Dominic Carlin Nandita M. deSouza Katja N. De Paepe Michelle R. Goulart Christine Hughes Ahmet Imrali Rhiannon Roberts Maria Pawula Richard Houghton Cheryl Lawrence Yathushan Yogeswaran Kelly Mousa Carike Coetzee Peter Sasieni Aaron Prendergast David J. Propper
author_sort	Hemant M. Kocher
title	Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
title_short	Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
title_full	Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
title_fullStr	Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
title_full_unstemmed	Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
title_sort	phase i clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/7c7d3ad82a9e4375ae3a8da492b9ac27
work_keys_str_mv	AT hemantmkocher phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT bristibasu phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT fiekeemfroeling phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT debashissarker phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT sarahslater phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT dominiccarlin phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT nanditamdesouza phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT katjandepaepe phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT michellergoulart phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT christinehughes phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT ahmetimrali phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT rhiannonroberts phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT mariapawula phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT richardhoughton phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT cheryllawrence phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT yathushanyogeswaran phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT kellymousa phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT carikecoetzee phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT petersasieni phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT aaronprendergast phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer AT davidjpropper phaseiclinicaltrialrepurposingalltransretinoicacidasastromaltargetingagentforpancreaticcancer
_version_	1718377633410973696

Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer

Ejemplares similares